[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"blood-vessel-prosthesis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:blood-vessel-prosthesis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100582686","vip---vascular-infection-project-100582686",false,"NCT06866535","VIP - Vascular Infection Project","VIP - Vascular Infection Project : Prospective Multicentric Database on Vascular Infections","Cohorte VIP","Inclusion Criteria:\n\n* ≥ 18 years-old;\n* all patients with a vascular infection, either native (aortitis, arteritis) or prosthetic (vascular graft, endograft and\u002For stent),\n* oral consent\n\nExclusion Criteria:\n\n* patient under legal protection","ALL","18 Years",{"count":20,"type":21},1000,"ESTIMATED","OBSERVATIONAL","Constitution of a prospective multicentric observational database to study vascular infections, both native, especially aortitis, and vascular graft and endograft infections. Clinical and paraclinical data on medical, surgical, anesthetic and intensive care management will be collected in order to better characterize these infections",[25,26,27,28],"Aortitis","Vascular Graft Infection","Blood Vessel Prosthesis","Infections",[30,31,32],"vascular graft and endograft infections","infectious aortitis","infectious arteritis","RECRUITING","2025-03-05",{"date":36,"type":37},"2025-03-10","ACTUAL",{"date":39,"type":37},"2022-05-10",{"date":41,"type":21},"2032-05-10",{"name":43,"class":44},"University Hospital, Bordeaux","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":58,"phases":59,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":45},"100511368","sirolimus-drug-coated-balloon-versus-stent-graft-100511368","NCT05938530","Sirolimus Drug-coated Balloon Versus Stent Graft","Sirolimus Drug-coated Balloon Versus Stent Graft for Thrombosed Arteriovenous Graft (SUSTAIN)","SUSTAIN","Inclusion Criteria:\n\n* Thrombosed AVG in the upper arm\n* Successful thrombolysis of the thrombosed AVG, defined as the re-established of flow on Digital Subtraction Angiography (DSA) and restoration of thrill in the AVG on clinical examination (to be determined during procedure)\n\nExclusion Criteria:\n\n* Patient unable to provide informed consent\n* Previous bare metal stent or stent-graft placement within the dialysis access\n* Previous treatment with DCB within 3 months\n* Presence of central vein stenosis which cannot be adequately treated (residual recoil of more than 30%)\n* Failure to re-establish blood flow\n* Failure to adequately treat the GV junction (defined as residual stenosis of more than 30%)\n* Sepsis or active infection\n* Recent intracranial bleed or gastrointestinal bleed within the past 12 months\n* Allergy to iodinated contrast media, anti-platelet drugs, heparin or sirolimus\n* Pregnancy\n* Life expectancy \\\u003C 12 months based on physician's estimate (eg. active malignancy)","21 Years","85 Years",{"count":57,"type":21},100,"INTERVENTIONAL",[60],"NA","A functioning dialysis vascular access is critical to the delivery of lifesaving hemodialysis. Arteriovenous graft (AVG) is a surgically created vascular access used for hemodialysis in patients with end-stage renal disease. AVG thrombosis due to underlying flow-limiting stenosis of the graft vein junction and outflow veins is a common complication. Thrombosed AVG can be treated with thrombolysis combined with percutaneous transluminal angioplasty with good immediate success rates. However, the mid-to-long term patency rates following angioplasty have been suboptimal. Sirolimus drug-coated balloon has been shown to be safe and effective in the salvage of thrombosed arteriovenous graft. The investigators hypothesize that sirolimus drug-coated balloon is non-inferior to stent graft in maintaining the patency of thrombosed AVG that is successfully salvaged. This study is conducted to compare the 6-month access circuit primary patency of thrombosed AVG treated with sirolimus drug-coated balloon versus stent graft.",[63,27],"Arteriovenous Shunt Thrombosis",[65,66,67,68,69],"Arteriovenous graft","Thrombosis","Sirolimus","Drug-coated balloon","stent graft","2023-12-19",{"date":72,"type":37},"2023-12-26",{"date":74,"type":37},"2023-11-01",{"date":76,"type":21},"2026-08",{"name":78,"class":44},"Singapore General Hospital"]